Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 5/2013

01.10.2013 | ORIGINAL ARTICLE

Angiotensin II Type 2 Receptor (AT2R) is Associated with Increased Tolerance of the Hyperthyroid Heart to Ischemia-Reperfusion

verfasst von: Felix Meira Tavares, Ivson Bezerra da Silva, Dayane Aparecida Gomes, Maria Luiza Morais Barreto-Chaves

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Thyroid hormone induces cardiac hypertrophy and preconditions the myocardium against Ischemia/Reperfusion (I/R) injury. Type 2 Angiotensin II receptors (AT2R) are shown to be upregulated in cardiac hypertrophy observed in hyperthyroidism and this receptor has been reported to mediate cardioprotection against ischemic injury.

Methods

The aim of the present study was to evaluate the role of AT2R in the recovery of myocardium after I/R in isolated hearts from T3 treated rats. Male Wistar rats were treated with triiodothyronine (T3; 7 μg/100 g BW/day, i.p.) in the presence or not of a specific AT2R blocker (PD123,319; 10 mg/Kg) for 14 days, while normal rats served as control. After treatment, isolated hearts were perfused in Langendorff mode; after 30 min of stabilization, hearts were subjected to 20 min of zero-flow global ischemia followed by 25 min, 35 min and 45 min of reperfusion.

Results

T3 treatment induced cardiac hypertrophy, which was not changed by PD treatment. Post-ischemic recovery of cardiac function was increased in T3-treated hearts after 35 min and 45 min of reperfusion as compared to control and the ischemic contracture was accelerated and intensified. AT2R blockade was able to return the evaluated functional parameters of cardiac performance (LVDP, +dP/dtmáx and −dP/dtmin) to the control condition. Furthermore, AT2R blockade prevented the increase in AMPK expression levels induced by T3, suggesting its possible involvement in this process.

Conclusion

AT2R plays a significant role in T3-induced cardioprotection.
Literatur
1.
Zurück zum Zitat Dillmann W. Cardiac hypertrophy and thyroid hormone signaling. Heart Fail Rev. 2010;15:125–32.PubMedCrossRef Dillmann W. Cardiac hypertrophy and thyroid hormone signaling. Heart Fail Rev. 2010;15:125–32.PubMedCrossRef
2.
Zurück zum Zitat Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res. 2004;59:31–50.PubMedCrossRef Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res. 2004;59:31–50.PubMedCrossRef
3.
4.
Zurück zum Zitat Klein I, Ojamaa K. Thyroid hormone: targeting the vascular smooth muscle cell. Circ Res. 2001;88:260–1.PubMedCrossRef Klein I, Ojamaa K. Thyroid hormone: targeting the vascular smooth muscle cell. Circ Res. 2001;88:260–1.PubMedCrossRef
5.
Zurück zum Zitat Buser PT, Wikman-Coffelt J, Wu ST, Derugin N, Parmley WW, Higgins CB. Postischaemic recovery of mechanical performance and energy metabolism in the presence of left ventricular hypertrophy. A 31P-MRS study. Circ Res. 1990;66:735–46.PubMedCrossRef Buser PT, Wikman-Coffelt J, Wu ST, Derugin N, Parmley WW, Higgins CB. Postischaemic recovery of mechanical performance and energy metabolism in the presence of left ventricular hypertrophy. A 31P-MRS study. Circ Res. 1990;66:735–46.PubMedCrossRef
6.
Zurück zum Zitat Pantos C, Mourouzis I, Tzeis S, et al. Propranolol diminishes cardiac hypertrophy but does not abolish acceleration of the ischaemic contracture in hyperthyroid hearts. J Cardiovasc Pharmacol. 2000;36:384–9.PubMedCrossRef Pantos C, Mourouzis I, Tzeis S, et al. Propranolol diminishes cardiac hypertrophy but does not abolish acceleration of the ischaemic contracture in hyperthyroid hearts. J Cardiovasc Pharmacol. 2000;36:384–9.PubMedCrossRef
7.
Zurück zum Zitat Venditti P, Masullo P, Agnisola C, Di Meo S. Effect of vitamin E on the response to ischaemia-reperfusion of Langendorff heart preparations from hyperthyroid rats. Life Sci. 2000;66:697–708.PubMedCrossRef Venditti P, Masullo P, Agnisola C, Di Meo S. Effect of vitamin E on the response to ischaemia-reperfusion of Langendorff heart preparations from hyperthyroid rats. Life Sci. 2000;66:697–708.PubMedCrossRef
8.
Zurück zum Zitat Pantos C, Malliopoulou V, Mourouzis I, et al. Long-term thyroxine administration protects the heart in a similar pattern as ischaemic preconditioning. Thyroid. 2002;12:325–9.PubMedCrossRef Pantos C, Malliopoulou V, Mourouzis I, et al. Long-term thyroxine administration protects the heart in a similar pattern as ischaemic preconditioning. Thyroid. 2002;12:325–9.PubMedCrossRef
9.
Zurück zum Zitat Pantos C, Malliopoulou V, Paizis I, et al. Thyroid hormone and cardioprotection: study of p38 MAPK and JNKs during ischaemia and at reperfusion in isolated rat heart. Mol Cell Biochem. 2003;242:173–80.PubMedCrossRef Pantos C, Malliopoulou V, Paizis I, et al. Thyroid hormone and cardioprotection: study of p38 MAPK and JNKs during ischaemia and at reperfusion in isolated rat heart. Mol Cell Biochem. 2003;242:173–80.PubMedCrossRef
10.
Zurück zum Zitat Sirlak M, Yazicoglu L, Inan MB, et al. Oral thyroid hormone pretreatment in left ventricular dysfunction. Eur J Cardiothorac Surg. 2004;26:720–5.PubMedCrossRef Sirlak M, Yazicoglu L, Inan MB, et al. Oral thyroid hormone pretreatment in left ventricular dysfunction. Eur J Cardiothorac Surg. 2004;26:720–5.PubMedCrossRef
11.
Zurück zum Zitat Pantos C, Malliopoulou V, Varonos DD, Cokkinos DV. Thyroid hormone and phenotypes of cardioprotection. Basic Res Cardiol. 2004;99:101–20.PubMedCrossRef Pantos C, Malliopoulou V, Varonos DD, Cokkinos DV. Thyroid hormone and phenotypes of cardioprotection. Basic Res Cardiol. 2004;99:101–20.PubMedCrossRef
12.
Zurück zum Zitat Barreto-Chaves ML, Carrillo-Sepúlveda MA, Carneiro-Ramos MS, Gomes DA, Diniz GP. The crosstalk between thyroid hormones and the renin-angiotensin system. Vascul Pharmacol. 2010;52:166–70.PubMedCrossRef Barreto-Chaves ML, Carrillo-Sepúlveda MA, Carneiro-Ramos MS, Gomes DA, Diniz GP. The crosstalk between thyroid hormones and the renin-angiotensin system. Vascul Pharmacol. 2010;52:166–70.PubMedCrossRef
13.
Zurück zum Zitat Hu LW, Benvenutti LA, Liberti EA, Carneiro-Ramos MS, Barreto-Chaves ML. Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling. Am J Physiol Regul Integr Comp Physiol. 2003;285:R1473–80.PubMed Hu LW, Benvenutti LA, Liberti EA, Carneiro-Ramos MS, Barreto-Chaves ML. Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling. Am J Physiol Regul Integr Comp Physiol. 2003;285:R1473–80.PubMed
14.
Zurück zum Zitat Diniz GP, Carneiro-Ramos MS, Barreto-Chaves ML. Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/GSK-3beta/mTOR signaling pathway. Basic Res Cardiol. 2009;104:653–67.PubMedCrossRef Diniz GP, Carneiro-Ramos MS, Barreto-Chaves ML. Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/GSK-3beta/mTOR signaling pathway. Basic Res Cardiol. 2009;104:653–67.PubMedCrossRef
15.
Zurück zum Zitat Carneiro-Ramos MS, Diniz GP, Nadu AP, et al. Blockage of angiotensin II type 2 receptor prevents thyroxine-mediated cardiac hypertrophy by blocking Akt activation. Basic Res Cardiol. 2010;105:325–35.PubMedCrossRef Carneiro-Ramos MS, Diniz GP, Nadu AP, et al. Blockage of angiotensin II type 2 receptor prevents thyroxine-mediated cardiac hypertrophy by blocking Akt activation. Basic Res Cardiol. 2010;105:325–35.PubMedCrossRef
16.
Zurück zum Zitat De Gasparato M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415–72. De Gasparato M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415–72.
17.
Zurück zum Zitat Gross V, Obst M, Luft FC. Insights into angiotensin II receptor function through AT2 receptor knockout mice. Acta Physiol Scand. 2004;181:487–94.PubMedCrossRef Gross V, Obst M, Luft FC. Insights into angiotensin II receptor function through AT2 receptor knockout mice. Acta Physiol Scand. 2004;181:487–94.PubMedCrossRef
18.
Zurück zum Zitat Steckelings UM, Widdop RE, Paulis L, Unger T. The angiotensin AT2 receptor in left ventricular hypertrophy. J Hypertens. 2010;28:S50–5.PubMedCrossRef Steckelings UM, Widdop RE, Paulis L, Unger T. The angiotensin AT2 receptor in left ventricular hypertrophy. J Hypertens. 2010;28:S50–5.PubMedCrossRef
19.
Zurück zum Zitat Yoshiyama M, Kim S, Yamagishi H, et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J. 1994;128:1–6.PubMedCrossRef Yoshiyama M, Kim S, Yamagishi H, et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J. 1994;128:1–6.PubMedCrossRef
20.
Zurück zum Zitat Yang BC, Phillips MI, Zhang YC, et al. Critical role of AT1 receptor expression after ischemia/reperfusion in isolated rat hearts: beneficial effect of antisense oligodeoxynucleotides directed at AT1 receptor mRNA. Circ Res. 1998;83:552–9.PubMedCrossRef Yang BC, Phillips MI, Zhang YC, et al. Critical role of AT1 receptor expression after ischemia/reperfusion in isolated rat hearts: beneficial effect of antisense oligodeoxynucleotides directed at AT1 receptor mRNA. Circ Res. 1998;83:552–9.PubMedCrossRef
21.
Zurück zum Zitat Xu Y, Kumar D, Dyck JR, Ford WR, Clanachan AS, Lopaschuk GD, et al. AT(1) and AT(2) receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts. Am J Physiol Heart Circ Physiol. 2002;282:H1206–15.PubMed Xu Y, Kumar D, Dyck JR, Ford WR, Clanachan AS, Lopaschuk GD, et al. AT(1) and AT(2) receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts. Am J Physiol Heart Circ Physiol. 2002;282:H1206–15.PubMed
22.
Zurück zum Zitat Przyklenk K, Kloner RA. “Cardioprotection” by ACE-inhibitors in acute myocardial ischemia and infarction? Basic Res Cardiol. 1993;88 Suppl 1:139–54.PubMed Przyklenk K, Kloner RA. “Cardioprotection” by ACE-inhibitors in acute myocardial ischemia and infarction? Basic Res Cardiol. 1993;88 Suppl 1:139–54.PubMed
23.
Zurück zum Zitat Pantos C, Paizis I, Mourouzis I, et al. Blockade of angiotensin II type 1 receptor diminishes cardiac hypertrophy, but does not abolish thyroxin-induced preconditioning. Horm Metab Res. 2005;37:500–4.PubMedCrossRef Pantos C, Paizis I, Mourouzis I, et al. Blockade of angiotensin II type 1 receptor diminishes cardiac hypertrophy, but does not abolish thyroxin-induced preconditioning. Horm Metab Res. 2005;37:500–4.PubMedCrossRef
24.
Zurück zum Zitat Langendorff O. Untersuchungen an uberlebenden Saugethierherzen. Pflügers Arch. 1895;61:291–332.CrossRef Langendorff O. Untersuchungen an uberlebenden Saugethierherzen. Pflügers Arch. 1895;61:291–332.CrossRef
25.
Zurück zum Zitat Fallen EL, Elliot WC, Gorlin R. Apparatus for study of ventricular function and metabolism in the isolated perfused rat heart. J Appl Physiol. 1967;22:836–9.PubMed Fallen EL, Elliot WC, Gorlin R. Apparatus for study of ventricular function and metabolism in the isolated perfused rat heart. J Appl Physiol. 1967;22:836–9.PubMed
26.
Zurück zum Zitat Carrillo-Sepulveda MA, Ceravolo GS, Furstenau CR, et al. Emerging role of angiotensin type 2 receptor (AT2R) /Akt/ NO pathway in vascular smooth muscle cell in the hyperthyroidism. PLoS One. 2013;8:e61982.PubMedCrossRef Carrillo-Sepulveda MA, Ceravolo GS, Furstenau CR, et al. Emerging role of angiotensin type 2 receptor (AT2R) /Akt/ NO pathway in vascular smooth muscle cell in the hyperthyroidism. PLoS One. 2013;8:e61982.PubMedCrossRef
27.
Zurück zum Zitat Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest. 1997;9:1926–35.CrossRef Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest. 1997;9:1926–35.CrossRef
28.
Zurück zum Zitat Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.PubMedCrossRef Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.PubMedCrossRef
29.
Zurück zum Zitat Opie LH. Cardioprotection at a distance—remote conditioning takes the stage. Exp Physiol. 2012;97:905.PubMedCrossRef Opie LH. Cardioprotection at a distance—remote conditioning takes the stage. Exp Physiol. 2012;97:905.PubMedCrossRef
30.
Zurück zum Zitat Pantos C, Malliopoulou V, Mourouzis I, et al. Hyperthyroid hearts display a phenotype of cardioprotection against ischemic stress: a possible involvement of heat shock protein 70. Horm Metab Res. 2006;38:308–13.PubMedCrossRef Pantos C, Malliopoulou V, Mourouzis I, et al. Hyperthyroid hearts display a phenotype of cardioprotection against ischemic stress: a possible involvement of heat shock protein 70. Horm Metab Res. 2006;38:308–13.PubMedCrossRef
31.
Zurück zum Zitat Barreto-Chaves ML, de Souza MP, Fürstenau CR. Acute actions of thyroid hormone on blood vessel biochemistry and physiology. Curr Opin Endocrinol Diabetes Obes. 2011;18:300–3.PubMedCrossRef Barreto-Chaves ML, de Souza MP, Fürstenau CR. Acute actions of thyroid hormone on blood vessel biochemistry and physiology. Curr Opin Endocrinol Diabetes Obes. 2011;18:300–3.PubMedCrossRef
32.
Zurück zum Zitat Diniz GP, Carneiro-Ramos MS, Barreto-Chaves ML. Angiotensin type 1 (AT1) and type 2 (AT2) receptors mediate the increase in TGF-B1 in thyroid hormone-induced cardiac hypertrophy. Pflugers Arch - Eur J Physiol. 2007;454:75–81.CrossRef Diniz GP, Carneiro-Ramos MS, Barreto-Chaves ML. Angiotensin type 1 (AT1) and type 2 (AT2) receptors mediate the increase in TGF-B1 in thyroid hormone-induced cardiac hypertrophy. Pflugers Arch - Eur J Physiol. 2007;454:75–81.CrossRef
33.
Zurück zum Zitat Murphy TJ, Takeuchi K, Alexander RW. Molecular cloning of AT1 angiotensin receptors. Am J Hypertens. 1992;5:236S–42.PubMed Murphy TJ, Takeuchi K, Alexander RW. Molecular cloning of AT1 angiotensin receptors. Am J Hypertens. 1992;5:236S–42.PubMed
34.
Zurück zum Zitat Kambayashi Y, Bardhan S, Takahashi K, et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem. 1993;268:24543–6.PubMed Kambayashi Y, Bardhan S, Takahashi K, et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem. 1993;268:24543–6.PubMed
35.
Zurück zum Zitat Siragy HM, Carey RM. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3′, 5′-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats. J Clin Invest. 1996;97:1978–82.PubMedCrossRef Siragy HM, Carey RM. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3′, 5′-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats. J Clin Invest. 1996;97:1978–82.PubMedCrossRef
36.
Zurück zum Zitat Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension. 1999;31:349–55.CrossRef Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension. 1999;31:349–55.CrossRef
37.
Zurück zum Zitat Batenburg WW, Garrelds IM, Bernasconi CC, et al. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation. 2004;109:2296–301.PubMedCrossRef Batenburg WW, Garrelds IM, Bernasconi CC, et al. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation. 2004;109:2296–301.PubMedCrossRef
38.
Zurück zum Zitat Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925–35.PubMedCrossRef Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925–35.PubMedCrossRef
39.
Zurück zum Zitat Akishita M, Horiuchi M, Yamada H, et al. Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol Genomics. 2000;2:13–20.PubMed Akishita M, Horiuchi M, Yamada H, et al. Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol Genomics. 2000;2:13–20.PubMed
40.
Zurück zum Zitat Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension. 2003;42:600–4.PubMedCrossRef Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension. 2003;42:600–4.PubMedCrossRef
41.
Zurück zum Zitat Hermann R, Marina Prendes MG, Torresin ME, Vélez D, Savino EA, Varela A. Effects of the AMP-activated protein kinase inhibitor compound C on the postconditioned rat heart. J Physiol Sci. 2012;62:333–41.PubMedCrossRef Hermann R, Marina Prendes MG, Torresin ME, Vélez D, Savino EA, Varela A. Effects of the AMP-activated protein kinase inhibitor compound C on the postconditioned rat heart. J Physiol Sci. 2012;62:333–41.PubMedCrossRef
42.
Zurück zum Zitat Thuc LC, Teshima Y, Takahashi N, et al. Cardioprotective effects of pravastatin against lethal ventricular arrhythmias induced by reperfusion in the rat heart. Circ J. 2011;75:1601–8.PubMedCrossRef Thuc LC, Teshima Y, Takahashi N, et al. Cardioprotective effects of pravastatin against lethal ventricular arrhythmias induced by reperfusion in the rat heart. Circ J. 2011;75:1601–8.PubMedCrossRef
43.
Zurück zum Zitat Oishi Y, Ozono R, Yano Y, et al. Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling. Hypertension. 2003;41:814–8.PubMedCrossRef Oishi Y, Ozono R, Yano Y, et al. Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling. Hypertension. 2003;41:814–8.PubMedCrossRef
44.
Zurück zum Zitat Calvert JW, Gundewar S, Jha S, et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes. 2008;57:696–705.PubMedCrossRef Calvert JW, Gundewar S, Jha S, et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes. 2008;57:696–705.PubMedCrossRef
45.
Zurück zum Zitat Gundewar S, Calvert JW, Jha S, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res. 2009;104:403–11.PubMedCrossRef Gundewar S, Calvert JW, Jha S, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res. 2009;104:403–11.PubMedCrossRef
46.
Zurück zum Zitat Olson AK, Bouchard B, Ning XH, Isern M, Rosiers CD, Portman MA. Triodothironine increases myocardial function and pyruvate entry into the citric acid cycle after reperfusion in a model of infant cardiopulmonary bypass. Am J Physiol Heart Circ Physiol. 2012;302:H1086–93.PubMedCrossRef Olson AK, Bouchard B, Ning XH, Isern M, Rosiers CD, Portman MA. Triodothironine increases myocardial function and pyruvate entry into the citric acid cycle after reperfusion in a model of infant cardiopulmonary bypass. Am J Physiol Heart Circ Physiol. 2012;302:H1086–93.PubMedCrossRef
Metadaten
Titel
Angiotensin II Type 2 Receptor (AT2R) is Associated with Increased Tolerance of the Hyperthyroid Heart to Ischemia-Reperfusion
verfasst von
Felix Meira Tavares
Ivson Bezerra da Silva
Dayane Aparecida Gomes
Maria Luiza Morais Barreto-Chaves
Publikationsdatum
01.10.2013
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 5/2013
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-013-6473-x

Weitere Artikel der Ausgabe 5/2013

Cardiovascular Drugs and Therapy 5/2013 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.